Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Congress Asset Management Co. MA

Congress Asset Management Co. MA raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 153,394 shares of the company’s stock after acquiring an additional 5,819 shares during the period. Congress Asset Management Co. MA owned 0.50% of Medpace worth $47,020,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MEDP. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Medpace by 2.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock valued at $2,114,000 after purchasing an additional 148 shares during the period. Portside Wealth Group LLC grew its stake in shares of Medpace by 14.8% during the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock valued at $435,000 after buying an additional 183 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Medpace by 355.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after buying an additional 2,774 shares during the last quarter. Norden Group LLC raised its position in shares of Medpace by 207.8% in the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock worth $1,537,000 after buying an additional 3,385 shares during the period. Finally, Eagle Asset Management Inc. boosted its holdings in Medpace by 155.0% in the fourth quarter. Eagle Asset Management Inc. now owns 226,435 shares of the company’s stock valued at $69,409,000 after acquiring an additional 137,632 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Down 0.0 %

MEDP stock traded down $0.19 during trading on Friday, reaching $393.91. The stock had a trading volume of 128,196 shares, compared to its average volume of 155,124. The firm has a fifty day moving average price of $394.04 and a 200 day moving average price of $358.60. The company has a market capitalization of $12.20 billion, a P/E ratio of 40.15, a PEG ratio of 1.95 and a beta of 1.39. Medpace Holdings, Inc. has a 1-year low of $214.32 and a 1-year high of $421.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter in the previous year, the firm posted $2.27 earnings per share. The company’s revenue was up 17.7% compared to the same quarter last year. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MEDP. TD Cowen began coverage on Medpace in a research note on Wednesday, May 29th. They set a “buy” rating and a $452.00 price target for the company. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. Guggenheim upped their price target on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Friday, June 7th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Medpace currently has an average rating of “Moderate Buy” and a consensus price target of $443.14.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 4,782 shares of the stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the transaction, the chief executive officer now directly owns 716,197 shares in the company, valued at approximately $286,894,194.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO August J. Troendle sold 4,782 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total value of $1,915,573.56. Following the sale, the chief executive officer now owns 716,197 shares in the company, valued at approximately $286,894,194.26. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle sold 3,987 shares of Medpace stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $395.22, for a total value of $1,575,742.14. Following the completion of the transaction, the chief executive officer now owns 660,351 shares of the company’s stock, valued at $260,983,922.22. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,621 shares of company stock worth $11,816,852. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.